Detrol: Regain Control Over Overactive Bladder Symptoms
Detrol
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 1.60 $ | 47.97 $ (0%) | 🛒 Add to cart |
| 60 | 1.35 $ | 95.94 $ 80.73 $ (16%) | 🛒 Add to cart |
| 90 | 1.26 $ | 143.91 $ 113.49 $ (21%) | 🛒 Add to cart |
| 120 | 1.23 $ | 191.88 $ 147.42 $ (23%) | 🛒 Add to cart |
| 180 | 1.18 $ | 287.82 $ 212.94 $ (26%) | 🛒 Add to cart |
| 270 | 1.16 $ | 431.73 $ 312.39 $ (28%) | 🛒 Add to cart |
| 360 | 1.15 $
Best per pill | 575.64 $ 413.01 $ (28%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 2.57 $ | 77.22 $ (0%) | 🛒 Add to cart |
| 60 | 2.16 $ | 154.44 $ 129.87 $ (16%) | 🛒 Add to cart |
| 90 | 2.04 $ | 231.66 $ 183.69 $ (21%) | 🛒 Add to cart |
| 120 | 1.97 $ | 308.88 $ 236.34 $ (23%) | 🛒 Add to cart |
| 180 | 1.90 $ | 463.32 $ 341.64 $ (26%) | 🛒 Add to cart |
| 270 | 1.85 $ | 694.98 $ 499.59 $ (28%) | 🛒 Add to cart |
| 360 | 1.83 $
Best per pill | 926.64 $ 657.54 $ (29%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 4.29 $ | 128.70 $ (0%) | 🛒 Add to cart |
| 60 | 3.33 $ | 257.40 $ 200.07 $ (22%) | 🛒 Add to cart |
| 90 | 3.00 $ | 386.10 $ 270.27 $ (30%) | 🛒 Add to cart |
| 120 | 2.84 $ | 514.80 $ 340.47 $ (34%) | 🛒 Add to cart |
| 180 | 2.67 $ | 772.20 $ 480.87 $ (38%) | 🛒 Add to cart |
| 270 | 2.57 $
Best per pill | 1158.30 $ 693.81 $ (40%) | 🛒 Add to cart |
Synonyms | |||
Detrol (tolterodine tartrate) is a prescription medication specifically formulated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. As a competitive, specific muscarinic receptor antagonist, it works by relaxing the detrusor muscle in the bladder wall, thereby increasing bladder capacity and reducing involuntary contractions. This targeted mechanism of action provides a scientifically-backed approach to managing disruptive OAB symptoms, allowing for a significant improvement in quality of life and daily functioning for appropriate patients.
Features
- Active pharmaceutical ingredient: Tolterodine tartrate
- Available in immediate-release (Detrol) and extended-release (Detrol LA) tablet formulations
- Standard immediate-release dosage: 1 mg and 2 mg tablets
- Standard extended-release dosage: 2 mg and 4 mg capsules
- Prescription-only medication requiring healthcare provider authorization
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Significantly reduces episodes of urge urinary incontinence, helping to prevent accidental leaks.
- Decreases the sudden, strong need to urinate immediately (urgency), allowing for better planning and reduced anxiety.
- Increases the time between bathroom visits (reduces frequency), enabling longer uninterrupted periods for work, sleep, and social activities.
- Improves functional bladder capacity, meaning the bladder can hold more urine before signaling the need to void.
- Enhances overall quality of life by reducing the psychological burden and social limitations associated with OAB.
- Provides 24-hour coverage with once-daily dosing in the extended-release formulation, supporting medication adherence.
Common use
Detrol is primarily prescribed for the management of overactive bladder syndrome characterized by symptoms of urinary urgency, urinary frequency, and urge incontinence. It is indicated for adults who experience these symptoms due to idiopathic detrusor overactivity or neurogenic causes. The medication is typically used when behavioral modifications (such as bladder training, pelvic floor exercises, and fluid management) alone have provided insufficient symptom control. Healthcare providers may prescribe Detrol as part of a comprehensive treatment plan that includes lifestyle modifications and monitoring for optimal therapeutic outcomes.
Dosage and direction
The recommended dosage for Detrol immediate-release tablets is 2 mg twice daily. For patients with impaired liver function or who are taking certain CYP3A4 inhibitors, the dose should be reduced to 1 mg twice daily. The extended-release capsules (Detrol LA) are typically prescribed at 4 mg once daily, which may be reduced to 2 mg once daily based on individual tolerance or specific patient factors. Tablets should be swallowed whole with water and may be taken with or without food, though consistency in administration relative to meals is recommended. Dosage adjustments should only be made under medical supervision based on therapeutic response and tolerability. Treatment response is usually evaluated within 4-8 weeks of initiation.
Precautions
Patients should inform their healthcare provider of any history of urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, as Detrol is contraindicated in these conditions. Use with caution in patients with clinically significant bladder outflow obstruction due to risk of urinary retention, gastrointestinal obstructive disorders, renal impairment, hepatic impairment, or autonomic neuropathy. Monitor for decreased gastrointestinal motility in patients with conditions such as severe constipation. Caution is advised when prescribing to patients with myasthenia gravis or other conditions that might be exacerbated by anticholinergic effects. Elderly patients may be more sensitive to the anticholinergic effects of tolterodine. Regular assessment of therapeutic response and potential side effects is recommended throughout treatment.
Contraindications
Detrol is contraindicated in patients with known hypersensitivity to tolterodine tartrate or any component of the formulation. It is absolutely contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. The medication should not be used in patients with severe hepatic impairment (Child-Pugh Class C). Concomitant use with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin) is contraindicated due to significantly increased tolterodine exposure. Use is contraindicated in patients with known QT prolongation or who are taking medications that prolong the QT interval.
Possible side effect
The most common side effects associated with Detrol are dry mouth (approximately 35% of patients), headache (approximately 11%), constipation (approximately 7%), and abdominal pain (approximately 7%). Other frequently reported adverse reactions include dry eyes, dyspepsia, somnolence, dizziness, and blurred vision. Less common but potentially serious side effects may include urinary retention, angioedema, QT prolongation, and central nervous system effects such as confusion and hallucinations in susceptible individuals. The extended-release formulation may have a slightly different side effect profile due to its modified release characteristics. Most side effects are dose-dependent and often diminish with continued therapy or dose adjustment.
Drug interaction
Detrol is primarily metabolized by cytochrome P450 2D6 (CYP2D6) and 3A4 (CYP3A4) enzymes, making it susceptible to interactions with inhibitors or inducers of these pathways. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) significantly increase tolterodine exposure and are contraindicated. Moderate CYP3A4 inhibitors (erythromycin, fluconazole, aprepitant) may require dose reduction. Other anticholinergic medications may potentiate both therapeutic and adverse effects. Drugs that prolong the QT interval (certain antiarrhythmics, antipsychotics, antibiotics) may have additive effects. Fluoxetine and other CYP2D6 inhibitors may moderately increase tolterodine concentrations. Warfarin monitoring may be advised due to potential interaction.
Missed dose
If a dose of Detrol is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. For patients taking the twice-daily formulation, if remembered within a few hours of the missed dose, take it immediately. For the once-daily extended-release formulation, take it when remembered unless the next dose is due within 12 hours. Consistent daily administration is important for maintaining therapeutic effect, so patients should establish routines to support adherence.
Overdose
Overdose with tolterodine may result in severe anticholinergic effects including central nervous system excitation, flushing, dilated pupils, gastrointestinal hypermotility, urinary retention, and cardiac effects such as tachycardia. In severe cases, QT prolongation, seizures, or respiratory depression may occur. Management should include gastric lavage or activated charcoal if presented early, along with symptomatic and supportive care. ECG monitoring is recommended to detect potential QT prolongation. Physostigmine may be considered for severe central anticholinergic effects in consultation with a poison control center. Dialysis is not expected to be effective due to tolterodine’s high protein binding and extensive distribution.
Storage
Store Detrol tablets and capsules at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any medication that is no longer needed or has expired through medication take-back programs or according to FDA-recommended disposal methods.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Detrol is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and only a healthcare provider can determine the appropriate therapy based on a patient’s specific medical condition, history, and current medications. Patients should not initiate, discontinue, or change dosage without consulting their healthcare provider. Report any adverse effects to your physician promptly.
Reviews
Clinical studies have demonstrated that Detrol significantly reduces weekly incontinence episodes and micturition frequency compared to placebo. In randomized controlled trials, patients treated with tolterodine 2 mg twice daily experienced approximately 50% reduction in incontinence episodes and 20% reduction in micturition frequency. The extended-release formulation provides equivalent efficacy with potentially improved tolerability due to more stable plasma concentrations. Many patients report meaningful improvements in quality of life measures, including reduced embarrassment, improved sleep, and increased participation in social activities. However, individual experiences vary, and some patients may not achieve adequate symptom control or may experience bothersome side effects requiring alternative treatments.